Indivior (INDV) director Mark Stejbach receives 3,722 RSUs in equity grant

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. director Mark Stejbach reported a grant of 3,722 shares of common stock in the form of Restricted Stock Units on January 26, 2026 at a price of $0 per share. Following this award, he beneficially owns 20,569 common shares in total.

Each RSU represents the right to receive one share of common stock and will vest on the day immediately before the first annual stockholders’ meeting after the grant date, as long as Stejbach continues serving the company through that vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Stejbach Mark

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,722	$0.00	--

Holdings After Transaction: Common Stock — 20,569 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stejbach Mark

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		A		3,722(1)	A	$0	20,569	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.

Remarks:

	/s/ Jordan Saltzberg, Power of Attorney	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did INDV director Mark Stejbach report on this Form 4?

Mark Stejbach reported receiving a grant of 3,722 Restricted Stock Units, each representing one share of Indivior Pharmaceuticals common stock. The grant was recorded as an acquisition at a price of $0 per share on January 26, 2026.

How many Indivior (INDV) shares does Mark Stejbach beneficially own after this transaction?

After the RSU grant, Mark Stejbach beneficially owns 20,569 shares of Indivior Pharmaceuticals common stock. This total reflects the newly awarded 3,722 RSUs in addition to his prior holdings, as reported in the Form 4 filing.

What are the vesting terms of the RSUs granted to Indivior (INDV) director Mark Stejbach?

The Restricted Stock Units vest on the day immediately preceding the date of the first annual meeting of Indivior’s stockholders following the grant date. Vesting is contingent on Stejbach’s continued service to Indivior through that vesting date.

What does a price of $0 per share mean for the INDV RSU grant to Mark Stejbach?

The reported price of $0 per share indicates this is an equity compensation award, not a market purchase. Stejbach is not paying cash for the shares; he receives them as compensation, subject to the RSUs’ vesting conditions.

Is Mark Stejbach’s ownership in Indivior (INDV) direct or indirect after this RSU grant?

The Form 4 indicates Stejbach’s ownership as direct (D) following the transaction. There is no noted intermediary entity or indirect ownership structure for these 20,569 shares in the provided disclosure.

What role does Mark Stejbach hold at Indivior Pharmaceuticals (INDV) according to this filing?

Mark Stejbach is identified as a director of Indivior Pharmaceuticals, Inc. in the Form 4. The RSU grant represents part of his equity-based compensation for serving on the company’s board of directors.